HUMANIGEN, INC. (HGEN)

HGEN was delisted on the 25th of July, 2023.

• Market cap: $4.3M
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Humanigen Inc is a biopharmaceutical company engaged in the development of proprietary monoclonal antibodies for various oncology indications and to enhance T-cell therapies, making these treatments safer and cost-effective. It focuses on preventing the serious and potentially life-threatening side effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005. It has one segment, which is related to the development of pharmaceutical products.

Employees: 6